| RPP # (Date) | Requirement Topic | Submission Due Date |
|---|
| Publication Name | Publication Topic | Anticipated Release Date |
|---|
| RPP # (Date) | Requirement Topic | Closed Date |
|---|---|---|
| RPP-24-05-N95 (08/02/2024) | Sustainment of N95 Respirator Manufacturing Capacity | 22 August, 2024 |
| RPP-24-07-mAbs (06/24/2024) | Manufacturing Optimization for Filovirus Monoclonal Antibodies | 5 August 2024 |
| RPP-24-06-Pipette (06/27/2024) | Industrial Base Expansion of injection molded pipette tips and centrifuge tubes for use in the vaccine manufacturing and pandemic response supply chain | 07/25/2024 |
RPP-24-03-Sterilization | Sterilization Capacity for Vaccines and Therapeutics | 3/28/2024 |
RPP-24-02-KSM-API | Production of Drug Substances and Drug Products at Commercial Scale | 3/20/2024 |
| RPP-24-01-SmallMol (01/11/2024) | Production of Biologically Derived Small Molecule Regulatory Starting Materials and/or Active Pharmaceutical Ingredients at Commercial Scale | 02/01/2024 |
| Survey | Market Research Topic | Closing Date |
|---|---|---|
| Request for Information: Antimicrobial Production and Supply | This RFI seeks information that will aid in improving the understanding of current domestic production capabilities and capacities of the domestic Public Health Industrial Base (PHIB) that specifically support the production and supply of antimicrobials. | 12/02/2024 |
Market Research Survey: Pichia Expression System Capabilities | The BioMaP-Consortium is particularly interested in understanding current capabilities and expertise in utilizing Pichia pastoris for biologics and vaccine production. If your organization has experience or capabilities in using Pichia-based expression systems, we would appreciate your responses to the following survey. | 11/21/2024 |
